AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma

Daniel L. Albertus, Christopher W. Seder, Guoan Chen, Xiaoju Wang, Wibisono Hartojo, Lin Lin, Amy Silvers, Daffyd G. Thomas, Thomas J. Giordano, Andrew C. Chang, Mark B. Orringer, William L. Bigbee (+2 others)
2008 Journal of Thoracic Oncology  
The importance of ␣-2-glycoprotein 1, zinc (AZGP1) in lung adenocarcinoma (AD) remains largely unknown. Analysis of serum autoantibodies to tumor antigens combined with gene expression profiling of primary tumors may provide insight into the mechanisms underlying lung carcinogenesis and identify new AD biomarkers. Methods: T7 phage cDNA libraries were used to identify AZGP1 autoantibodies in the serum of 473 patients (192 ADs, 192 matched controls, and 89 additional ADs for confirmation of
more » ... ngs). AZGP1 mRNA expression was examined in 86 ADs and 10 control lung tissue samples using oligonucleotide microarrays. AZGP1 protein expression was studied in 230 tissue samples (222 ADs; 8 controls) with immunohistochemistry. Kaplan-Meier analyses were used to correlate circulating autoantibody and tissue mRNA production with survival. AD cell lines A549 and SKLU1 were treated with 5-aza-2Ј-deoxycytidine (5-AZA) and trichostatin A (TSA) to examine the role of promoter methylation and histone deacetylation in the expression of AZGP1. Real-time polymerase chain reaction was used to quantify the effects of treatment. Results: In patients with AD, AZGP1 autoantibodies were observed in 40% of serum samples. Autoantibody production correlated with improved overall 5-year survival (p ϭ 0.002) and improved survival in those with stage I to II disease (p ϭ 0.008). A verification analysis was performed for the survival benefit and found similar results with p values of 0.02 and 0.036, respectively. Although abundant mRNA expression was found in a subset of tumors, mRNA expression did not correlate with prognosis. In normal lung, AZGP1 mRNA and protein expression were low or absent, whereas in AD they were highly expressed in 31.3% and 42.8% of samples, respectively. To determine whether AZGP1 expression in this subset of tumors might be affected by epigenetic mechanisms, low AZGP1-expressing A549 and SKLU1 AD cell lines were treated with TSA and 5-AZA. A 713-fold and 169-fold increase in mRNA expression were noted on treatment with TSA, respectively. Treatment with 5-AZA had minimal effect on AZGP1 mRNA expression. Conclusions: The presence of AZGP1 serum autoantibody may be used as a prognostic marker in patients with AD. Furthermore, up-regulation of AZGP1 mRNA in AD may be affected by chromatin remodeling by means of histone acetylation. FIGURE 4. Oligonucleotide microarray analysis of 86 AD and 10 normal samples revealed that 31.3% of adenocarcinomas expressed AZGP1 at least two fold more than the controls. Samples 1 to 86, AD; samples 87 to 96, controls. AD, lung adenocarcinoma. FIGURE 5. AZGP1 protein staining was not detected in (A) normal lung tissues, but was seen in (B) and (C) 42.8% of AD, and (D) 8.3% of SCC by immunohistochemistry. AD, lung adenocarcinoma; SCC, lung squamous cell carcinoma.
doi:10.1097/jto.0b013e318189f5ec pmid:18978557 fatcat:hnrdihmax5bqvmbbfsrkluyfv4